INDV Indivior Pharmaceuticals, Inc.

8-K Current Report

Filed: March 13, 2026

Health Care

Pharmaceutical Preparations

Indivior Pharmaceuticals, Inc. (INDV) 8-K current report filed with SEC EDGAR on March 13, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Indivior pricing 0.625% convertible senior notes due 2031 — unusually low coupon signals strong investor demand or significant equity conversion premium
• Convertible structure means potential shareholder dilution if notes convert to common stock at maturity or trigger conditions

+1 more insights

Other Indivior Pharmaceuticals, Inc. 8-K Filings

8-K Mar 17, 2026

8-K Mar 12, 2026

8-K Feb 26, 2026

Get deeper insights on Indivior Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.